Comparative cytogenetic analysis between cyclophosphamide-sensitive and -resistant lines of acute myeloid leukemia in the Lewis Brown Norway hybrid rat

W. Kearns, T. Koelling, Andrew M Yeager

Research output: Contribution to journalArticle

2 Scopus citations


An animal model of acute myeloid leukemia (AML) has been developed in the Brown Norway (BN) rat and has successfully been introduced into the Lewis x BN F1 hybrid (LBN) and designated LBN AML. The original LBN AML is sensitive to the chemotherapeutic agent cyclophosphamide (CY). Recently, a CY-resistant cell line of LBN AML has been established. To characterize this animal model of human leukemia better, we analyzed and compared the chromosomal makeup of both the CY-sensitive and CY-resistant LBN AML lines. The CY-sensitive LBN AML cultures contained two cell lines - line I (88%): 41,XX,-1,-2,-9,del(12)(q16),+der(1)t(1;?8)(p13;q31), +der(2)t(2;9)(p11;q11); and line II (12%): 41,XX,-1,-2,-9,del(12),del(20)(q13)+der(1)t(1;?8)(p13;q31), +der(2)t(2;9)(p11;q11). The recently developed CY-resistant AML cells contained two cell lines - line I (88%): 41,XX,-1,-2,-9,del(3)(q36q42.1),del(4)(q42.2),?t(5;?)(q35;?), ?t(8;?)(q24;?),del(12)(q16),+der (1)t(1;?8)(p13;q31),+der(2)t(2;9) (p11;q11); and line II (12%): 42,XX (probably represents host contamination). The new chromosomal aberrations in the CY-resistant line I [del(3)(q36q42.1),del(4)(q42.2),?t(5;?)(q35;?), and ?t(8;?)(q24;?)] suggest a possible interrelationship between these secondary karyotypic abnormalities and acquisition of resistance to the chemotherapeutic agent.

Original languageEnglish (US)
Pages (from-to)290-295
Number of pages6
JournalGenes Chromosomes and Cancer
Issue number4
Publication statusPublished - 1990
Externally publishedYes


ASJC Scopus subject areas

  • Cancer Research
  • Genetics

Cite this